Hostname: page-component-848d4c4894-p2v8j Total loading time: 0.001 Render date: 2024-05-21T23:50:36.137Z Has data issue: false hasContentIssue false
  • English
  • Français

Therapeutic Alternatives for Difficult-to-Treat Depression: A Narrative Review of the State of the Evidence

Published online by Cambridge University Press:  07 November 2014

Michael E. Thase
Get access Rights & Permissions [Opens in a new window]

Abstract

Despite the large number of depressed patients who do not respond to first-line antidepressants, the evidence base of alternate strategies is quite thin. In this article, a simple 5-stage system for categorizing treatment-resistant depression (TRD) is described and the evidence pertaining to the major strategies currently utilized is summarized using four grades, ranging from D (case reports only) to A (multiple positive placebo-controlled trials). It is concluded that the level of evidence supporting many of the contemporary strategies used for TRD (eg, combinations of antidepressants and augmentation with medications such as pindolol, buspirone, or modafinil) is scanty at best. Even the fundamental question concerning “to augment or to switch” is not answerable with available data. It is noted that the best-documented treatments (ie, lithium augmentation, switching to a monoamine oxidase inhibitor, and electroconvulsive therapy) are among the least utilized. This state of affairs will improve with completion of the studies of Systematic Treatment Alternatives to Relieve Depression, a large multicenter study of difficult-to-treat depression funded by the National Institute of Mental Health. There is a need for greater collaboration among academicians and organizations, such as the American Psychiatric Association, the National Institute of Mental Health, and the pharmaceutical industry, to ensure that sufficient research is conducted so that clinician's choices for patients with TRD can be guided by empirical evidence.

Type
Review Article
Information
CNS Spectrums , Volume 9 , Issue 11 , November 2004 , pp. 808 - 821
Copyright
Copyright © Cambridge University Press 2004

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Hirschfeld, RM, Montgomery, SA, Aguglia, E, et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry. 2002;63:826–837.CrossRefGoogle ScholarPubMed
2. Corey-Lisle, PK, Birnbaum, HG, Greenberg, PE, Marynchenko, MB, Claxton, AJ. Identification of a claims data “signature” and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63:717–726.CrossRefGoogle ScholarPubMed
3. Katon, W, Von Korff, M, Lin, E, et al. Distressed high utilizers of medical care. DSM-III-R diagnoses and treatment needs. Gen Hosp Psychiatry. 1990;12:355–362.CrossRefGoogle ScholarPubMed
4. Miller, IW, Keitner, GI, Schatzherg, AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline and imipramine. J Clin Psychiatry. 1998;59:608–619.CrossRefGoogle ScholarPubMed
5. Thase, ME, Rush, AJ, Howland, RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry. 2002;59:233–239.CrossRefGoogle ScholarPubMed
6. Adli, M, Berghöfer, A, Linden, MA et al. , Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry. 2002;63:782–790.CrossRefGoogle ScholarPubMed
7. Crismon, ML, Trivedi, M, Pigott, TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry. 1999;60:142–156.CrossRefGoogle ScholarPubMed
8. Trivedi, MH, Kleiber, BA. Algorithm for the treatment of chronic depression. J Clin Psychiatry. 2001;62:22–29.Google ScholarPubMed
9. Depression Guideline Panel. Clinical practice guideline, no 5. Depression in Primary Care. Vol 2. Treatment of Major Depression. Rockville, MD: Department of Health and Human Services Agency for Health Care Policy and Research. 93-0551, 1993. AHCPR Publication No. 93–0551.Google Scholar
10. Frank, E, Prien, RF, Jarrett, RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48:851–855.CrossRefGoogle ScholarPubMed
11. Thase, ME, Sloan, DME, Kornstein, SG. Remission as the critical outcome of depression treatment. Psychopharmacol Bull. 2002;36(suppl 3):12–25.Google ScholarPubMed
12. Thase, ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 2002;63:95–103.CrossRefGoogle ScholarPubMed
13. Thase, ME, Friedman, ES, Howland, RH. Management of treatment-resistant depression: psychotherapeutic perspectives. J Clin Psychiatry. 2001;62(suppl 18):18–24.Google ScholarPubMed
14. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000;157( 4 suppl):1–45.Google Scholar
15. Fava, M, Davidson, KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996;19:179–200.CrossRefGoogle ScholarPubMed
16. Thase, ME, Rush, AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. J Clin Psychiatry. 1997;58(suppl 13):23–29.Google ScholarPubMed
17. Dyck, MJ. Treatment-resistant depression: a critique of current approaches. Aust N Z J Psychiatry. 1994:28:34–41.CrossRefGoogle ScholarPubMed
18. Rosenbaum, JF, Fava, M, Nierenberg, AA, Sachs, GS. Treatment-resistant mood disorders. In: Gabbard, GO, ed. Treatment of Psychiatric Disorders. Washington, DC: American Psychiatric Publishing; 2001:1307–1387.Google Scholar
19. Thase, ME, Rush, AJ. Treatment-resistant depression. In: Bloom, FE, Kupfer, DJ, editors. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:1081–1097.Google Scholar
20. Posternak, MA, Zimmerman, M. The effectiveness of switching antidepressants during remission: a case series of depressed patients who experienced intolerable side effects. J Affect Disord. 2002;69:237–240.CrossRefGoogle ScholarPubMed
21. Thase, ME, Howland, RH. Refractory depression: relevance of psychosocial factors and therapies. Psychiatr Ann. 1994;24:232–240.CrossRefGoogle Scholar
22. Keck, PE Jr, Nelson, EB, McElroy, SL. Advances in the pharmacologic treatment of bipolar depression. Biol Psychiatry. 2003;53:671–679.CrossRefGoogle ScholarPubMed
23. Rush, AJ, Trivedi, M, Fava, M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry. 2003;160:237.CrossRefGoogle ScholarPubMed
24. Gilmor, ML, Owens, MJ, Nemeroff, CB. Inhibition of norepinephrine uptake in patients with major depression treated with paroxetine. Am J Psychiatry. 2002;159:1702–1710.CrossRefGoogle ScholarPubMed
25. Nierenberg, AA, McLean, NE, Alpert, JE, Worthington, JJ, Rosenbaum, JF, Fava, M. Early nonresponse to fluoxetine as a predictor of poor 8-week out-come. Am J Psychiatry. 1995;152:1500–1503.Google Scholar
26. Quitkin, FM, Petkova, E, McGrath, PJ, et al. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003; 160:734–740.CrossRefGoogle ScholarPubMed
27. Thase, ME. Comparing the methods used to compare antidepressants. Psychopharmacol Bull. 2002;36(suppl 1):4–17.Google ScholarPubMed
28. Thase, ME, Kremer, C, Rodrigues, HE, the SSRI Failure Study Group. Mirtazapine versus sertraline after SSRI non-response. Poster presented: at annual meeting of the American College of Neuropsychopharmacology. December 10–14, 2000; San Juan, Puerto Rico.Google Scholar
29. Fredman, SJ, Fava, M, Kienke, AS, White, CN, Nierenberg, AA, Rosenbaum, JF. Partial response, nonresponse, and relapse with selective serotonin reup-take inhibitors in major depression: a survey of current “next-step” practices. J Clin Psychiatry. 2000; 61:403–408.CrossRefGoogle Scholar
30. Thase, ME, Trivedi, MH, Rush, AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12:185–219.CrossRefGoogle ScholarPubMed
31. Beasley, CM, Masica, DN, Heiligenstein, JH, Wheadon, DE, Zerbe, RL. Possible monoamine oxidase inhibitor-serotonin reuptake inhibitor interaction: fluoxetine clinical data and preclinical findings. J Clin Psychopharmacol. 1993;13:312–320.CrossRefGoogle ScholarPubMed
32. Harvey, AT, Rudolph, RL, Preskorn, SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry. 2000;57:503–509.CrossRefGoogle ScholarPubMed
33. Smith, D, Dempster, C, Glanville, J, Freemantle, N, Anderson, I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396–404.CrossRefGoogle ScholarPubMed
34. Thase, ME, Entsuah, AR, Rudolph, RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.CrossRefGoogle ScholarPubMed
35. de Montigny, C, Silverstone, PH, Debonnel, G, Blier, P, Bakish, D. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol. 1999;19:401–406.CrossRefGoogle ScholarPubMed
36. Mitchell, PB, Schweitzer, I, Butrows, G, Johnson, G, Polonowitz, A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2000;20:483–487.CrossRefGoogle Scholar
37. Nierenberg, AA, Feighner, JP, Rudolph, R, Cole, JO, Sullivan, J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol 1994; 14:419–423.CrossRefGoogle ScholarPubMed
38. Schweitzer, I, Burrows, G, Tuckwell, V, Polonowita, A, Flynn, P, George, T et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol. 2001;21:185–189.CrossRefGoogle ScholarPubMed
39. Thase, ME, Friedman, ES, Howland, RH. Venlafaxine and treatment-resistant depression. Depress Anxiety. 2000;12(suppl l):55–62.3.0.CO;2-X>CrossRefGoogle ScholarPubMed
40. Poirier, MF, Boyer, P. Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999;175:12–16.CrossRefGoogle ScholarPubMed
41. Thase, ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998;59:502–508.CrossRefGoogle ScholarPubMed
42. Thase, ME, Schutte, AJ, van der flier, S, Heukels, A. Remission with mirtazapine versus SSRIS: a meta-analysis on data of ore than 2500 depressed patients treated in randomised controlled trials. J Affect Disord. 2004;78(suppl 1):S136.Google Scholar
43. Guelfi, JD, Ansseau, M, Timmerman, L, Kørsgaard, S, The MirtazapineVenlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol.. 2001:21:425–431.CrossRefGoogle Scholar
44. Fava, M, Dunner, DL, Greist, JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry. 2001;62:413–420.CrossRefGoogle ScholarPubMed
45. Lam, RW, Hossie, H, Solomons, K, Yatham, LN. Citalopram and bupropionSR: Combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry. 2004;65:37–340.CrossRefGoogle ScholarPubMed
46. Clayton, AH, Pradko, JF, Croft, HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4):357–366.CrossRefGoogle ScholarPubMed
47. Coleman, CC, Cunningham, LA, Foster, VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry. 1999:11:205–215.CrossRefGoogle ScholarPubMed
48. Croft, H, Settle, E, Houser, T, Batey, SR, Donahue, RM, Ascher, JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999;21:643–658.CrossRefGoogle ScholarPubMed
49. Ferguson, JM, Shrivastava, RK, Stahl, SM, et al. Reemergence of sexual dys-function in patients with major depressive disorder: double blind comparison of nefazodone and sertraline. J Clin Psychiatry. 2001:62:24–29.CrossRefGoogle Scholar
50. Rush, AJ, Armitage, R, Gillin, JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry. 1998:44:3–14.CrossRefGoogle ScholarPubMed
51. Marangell, LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(suppl 18):12–17.Google ScholarPubMed
52. Kennedy, SH, McCann, SM, Masellis, M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on phannacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry. 2002;63:181–186.CrossRefGoogle ScholarPubMed
53. McGrath, PJ, Stewart, JW, Nunes, EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry. 1993;150:118–123.Google ScholarPubMed
54. Thase, ME, Mallinger, AG, McKnight, D, Himmelhoch, JM. Treatment of imipra-mine resistant recurrent depression: IV A double-blind, crossover study of tranylcypromine in anergic bipolar depression. Am J Psychiatry. 1992; 149:195–198.Google Scholar
55. Thase, M, Nolen, W. Tricyclic antidepressants and classical monoamine oxidase inhibitors: contemporary clinical use. In: Buckley, PF, Waddington, JL, eds. Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice. Oxford, England: Butterworth-Heinemann; 2000:85–99.Google Scholar
56. Fava, M. Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry. 2001;62(suppl 18):4–11.Google ScholarPubMed
57. Manji, HK, McNamara, R, Chen, G, Lenox, RH. Signalling pathways in the brain: cellular transduction of mood stabilisation in the treatment of manicdepressive illness. Aust N Z J Psychiatry. 1999;33(suppl):S65–S85.CrossRefGoogle ScholarPubMed
58. Goodwin, GM; Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2003;17:149–173.CrossRefGoogle Scholar
59. Thase, ME, Kupfer, DJ, Frank, E, Jarrett, DB. Treatment of imipramine-resistant recurrent depression: II. An open clinical trial of lithium augmentation. J Clin Psychiatry. 1989;50:413–417.Google Scholar
60. Bauer, M, Dopfmer, S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999;19:427–434.CrossRefGoogle ScholarPubMed
61. Fava, M, Alpert, J, Nierenberg, A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002;22:379–387.CrossRefGoogle ScholarPubMed
62. Nierenberg, AA, Papkostas, GI, Petersen, T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64:35–39.CrossRefGoogle ScholarPubMed
63. Fagiolini, A, Buysse, DJ, Frank, E, Houck, PR, Luther, JF, Kupfer, DJ. Tolerability of combined treatment with lithium and paroxetine in patients with bipolar disorder and depression. J Clin Psychopharmacol 2001;21:474–478.CrossRefGoogle ScholarPubMed
64. Ontiveros, A, Fontaine, R, Elie, R. Refractory depression: the addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand. 1991;83:188–192.CrossRefGoogle ScholarPubMed
65. Joffe, RT, Sokolov, ST. Thyroid hormone treatment of primary unipolar depression: a review. Int J Neuropsychopharmacol. 2000:3:143–147.CrossRefGoogle ScholarPubMed
66. Prange, AJ Jr.Novel uses of thyroid hormone in patients with affective disorders. Thyroid. 1996:6:537–543.CrossRefGoogle ScholarPubMed
67. Aronson, R, Offman, HJ, Joffe, RT, Naylor, D. Triiodothyronine augmentation in the treatment of refractory depression-a meta-analysis. Arch Gen Psychiatry. 1996;53:842–848.CrossRefGoogle ScholarPubMed
68. Joffe, RT, Singer, W, Levitt, AJ, MacDonald, C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387–393.CrossRefGoogle ScholarPubMed
69. Bouwer, C, Stein, DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J. 1997; 87(4 suppl):534–537, 540.Google ScholarPubMed
70. Dimitriou, EC, Dimitriou, CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol. 1998;18:465–469.CrossRefGoogle ScholarPubMed
71. Jacobsen, FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217–220.Google ScholarPubMed
72. Joffe, RT, Schuller, DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993:54:269–271.Google ScholarPubMed
73. Landén, M, Gjorling, G, Agren, H, Fahlen, T. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry. 1998;59:664–668.CrossRefGoogle ScholarPubMed
74. Landen, M, Eriksson, E, Agren, H, Fahlen, T. Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999;19:268–271.CrossRefGoogle ScholarPubMed
75. Appelberg, BG, Syvalahti, EK, Koskine, TE, Mehtonen, OP, Muhonen, TT, Naukkarinen, HH. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. J Ciin Psychiatry. 2001;62:448–452.Google ScholarPubMed
76. Myers, JE, Thase, ME. Risperidone: review of its therapeutic utility in depression. Psychopharmacol Bull. 2001;35:109–129.Google ScholarPubMed
77. Nelson, JC. The use of antipsychotic drugs in the treatment of depression. In: Zohar, J, Belmaker, RH, eds. Treating Resistant Depression. New York, NY: PMA Publishing Corporation; 1987:131–146.Google Scholar
78. Zhang, W, Perry, KW, Wong, DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal coretx. Neuropsychopharmocology. 2000:23:250–262.CrossRefGoogle Scholar
79. Shelton, RC, Tollefson, GD, Tohen, M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131–134.CrossRefGoogle ScholarPubMed
80. Tohen, M, Vieta, E, Calabrese, J, et al. Efficacy of olanzapine and olanzapinefluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–1088.CrossRefGoogle ScholarPubMed
81. Dreshfield, LJ, Wong, DT, Perry, KW, Engleman, EA. Enhancement of fluoxetine-dependent increase of extracellular serotonin (5-HT) levels by (-) pindolol, an antagonist at 5-HT1A receptors. Neurochemistry Res. 1996;21:557–562.CrossRefGoogle Scholar
82. Artigas, F, Perez, V, Alvarez, E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994:51:248–251.CrossRefGoogle ScholarPubMed
83. Berman, RM, Darnell, AM, Miller, HL, Anand, A, Charney, DS. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry. 1997;154:37–43.Google ScholarPubMed
84. Berman, RM, Anand, A, Cappiello, A, et al. The use of pindolol with fluoxetine in the treatment of major dperession: final results from a double-blind, placebo-controlled trial. Biol Psychiatry. 1999:45:1170–1177.CrossRefGoogle Scholar
85. Maes, M, Libbrecht, I, van Hunsel, F, Campens, D, Meltzer, HY. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol. 1999;19:177–182.CrossRefGoogle ScholarPubMed
86. Moreno, FA, Gelenberg, AJ, Bachar, K, Delgado, PL. Pindolol augmentation of treatment-resistant depressed patients. J Clin Psychiatry. 1997:58:437–439.CrossRefGoogle ScholarPubMed
87. Perez, V, Soler, J, Puigdemont, D, Alvarez, E, Artigas, F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastoms Afectius. Arch Gen Psychiatry. 1999;56:375–379.CrossRefGoogle ScholarPubMed
88. Martinez, D, Hwang, D, Mawlawi, O, et al. Differential occupancy of somatodendritic and postsynaptic 5HT1A receptors by pindolol: a dose-occupancy study witj [11C] WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 2001;24:209–229.CrossRefGoogle Scholar
89. Saper, CB, Scammell, TE. Modafinil: a drug in search of a mechanism. Sleep. 2004;27:11–12.Google ScholarPubMed
90. Menza, MA, Kaufman, KR, Castellanos, A. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry. 2000;61:378–381.CrossRefGoogle ScholarPubMed
91. DeBattista, C, Lembke, A, Solvason, H, Ghebremichael, R, Poirier, J. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004:24:87–90.CrossRefGoogle ScholarPubMed
92. DeBattista, C, Doghramji, K, Menza, MA, Rosenthal, MH, Fieve, RR; Modafinil in Depression Study Group. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003; 64:1057–1064.CrossRefGoogle Scholar
93. Fava, M, Thase, ME, DeBattista, C. A multicenter, placebo-controlled study of modafinil augmentation in SSRI partial responders with persistent fatigue and sleepiness. J Ciin Psychiatry. In press.Google Scholar
94. Peet, M, Horrobin, DEA dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry. 2002;59:913–919.CrossRefGoogle ScholarPubMed
95. Lam, RW, Wan, DD, Cohen, NL, Kennedy, SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry. 2002;63:685–693.CrossRefGoogle ScholarPubMed
96. Levitt, AJ, Joffe, RT, Kamil, R, Mclntyre, R. Do depressed subjects who have failed both fluoxetine and a tricyclic antidepressant respond to the combination? J Clin Psychiatry. 1999;60:613–616.CrossRefGoogle Scholar
97. Zajecka, JM, Jeffriess, H, Fawcett, J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a retrospective analysis. J Clin Psychiatry. 1995;56:338–343.Google ScholarPubMed
98. Nelson, JC, Mazure, CM, Bowers, MB, Jatlow, PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303–307.CrossRefGoogle ScholarPubMed
99. Nelson, JC, Mazure, CM, Jatlow, PI, Bowers, MB Jr, Price, LH. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004:55:296–300.CrossRefGoogle ScholarPubMed
100. Fava, GA, Grandi, S, Zielezny, M, Canestrari, R, Morphy, MA. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry. 1994:151:1295–1299.Google ScholarPubMed
101. Bodkin, JA, Lasser, RA, Wines, JD, Gardner, DM, Baldessarini, RJ. Combining serotonin reuptake inhibitors bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry. 1997;58:137–145.CrossRefGoogle ScholarPubMed
102. Marshall, RD, Liebowitz, MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol. 1996;16:80–81.CrossRefGoogle ScholarPubMed
103. Marshall, RD, Johannet, CM, Collins, PY, Smith, H, Kahn, DA, Douglas, CJ. Bupropion and sertraline combination treatment in refractory depression. J Psychopharmaeol. 1995;9:284–286.CrossRefGoogle ScholarPubMed
104. Spier, SA. Use of bupropion with SRIs and venlafaxine. Depress Anxiety. 1998;7:73–75.3.0.CO;2-6>CrossRefGoogle ScholarPubMed
105. Ferreri, M, Lavergne, F, Berlin, I, Payan, C, Puech, AJ. Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone. Acta Psychiatr Scand. 2001;103:66–72.CrossRefGoogle ScholarPubMed
106. Carpenter, LL, Yasmin, S, Price, LH. A double-blind, placebo-contolled study of antidepressant augmentation with mirtazapine. Biol Psychiatry. 2002; 51(2):183–188.CrossRefGoogle Scholar
107. Licht, RW, Qvitzau, S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmocology. 2002;161:143–151.CrossRefGoogle ScholarPubMed
108. Thase, ME, Friedman, ES, Howland, RH. Is depression-focused psychotherapy just an elaborate placebo? Econ Neurosci. 2001;3:52–61.Google Scholar
109. Keller, MB, McCullough, JP, Klein, DN, et al. A comparison of nefazo-done, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med. 2000;342:1462–1470.CrossRefGoogle ScholarPubMed
110. Thase, ME, Greenhouse, JB, Frank, E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry. 1997;54:1009–1015.CrossRefGoogle ScholarPubMed
111. Miklowitz, DJ, Simoneau, TL, George, EL, et al. Family-focused treatment of bipolar disorder: 1-year effects of a psychoeducational program in conjunction with pharmacotherapy. Biol Psychiatry. 2000;48:582–592.CrossRefGoogle ScholarPubMed
112. Perry, A, Tarrier, N, Morriss, R, McCarthy, E, Limb, K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. Br Med J. 1999;318:149–153.CrossRefGoogle ScholarPubMed
113. Paykel, ES, Scott, J, Teasdale, JD, et al. Prevention of relapse in residual depression by cognitive therapy. Arch Gen Psychiatry. 1999;56:829–835.CrossRefGoogle ScholarPubMed
114. Fava, GA, Rafanelli, C, Grandi, S, Canestrari, R, Morphy, MA. Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry. 1998;155:1443–1445.CrossRefGoogle ScholarPubMed
115. Prudic, J, Sackeim, HA, Devanand, P. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res. 1989;31:287–296.CrossRefGoogle Scholar
116. Prudic, J, Haskett, RF, Mulsant, B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153:985–992.Google ScholarPubMed
117. Mulsant, BH, Haskett, RF, Prudic, J, et al. Low use of neuroleptic drugs in the treatment of psychotic major depression. Am J Psychiatry. 1997;154:559–561.Google ScholarPubMed
118. Sackeim, HA, Prudic, J, Devanand, DP, Decina, P, Kerr, B, Malitz, S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmaeol. 1990;10:96–104.CrossRefGoogle ScholarPubMed
119. George, MS, Lisanby, SH, Sackeim, HA. Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry. 1999;56:300–311.CrossRefGoogle ScholarPubMed
120. Pridmore, S, Bruno, R, Turnier-Shea, Y, Reid, P, Rybak, M. Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode. Int J Neumpsychopharmacol. 2000;3:129–134.CrossRefGoogle ScholarPubMed
121. Gershon, AA, Dannon, PN, Grunhaus, L. Transcranial magnetic stimulation in the treatment of depression. Am J Psychiatry. 2003;160:835–845.CrossRefGoogle ScholarPubMed
122. Rush, AJ, George, MS, Sackeim, HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47:276–286.CrossRefGoogle ScholarPubMed
123. Sackeim, HA, Rush, AJ, George, MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmocology. 2001;25:713–728.CrossRefGoogle ScholarPubMed